New kind of medicine could shake up diabetes market

24 June 2021
2020_pills_tablets_bottles_biotech_manufacturing_production_big

French metabolic diseases biotech company Poxel (Euronext: POXEL) has secured approval for a first-in-class type 2 diabetes medicine, Twymeeg (imeglimin hydrochloride).

The Japanese regulator has approved an application based on data from the Phase III TIMES program, which included three pivotal trials to evaluate the efficacy and safety of the medicine.

In all three studies, Twymeeg met its primary endpoints and objectives and was observed to exhibit a favorable safety and tolerability profile.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical